Reviewing Genocea Biosciences (GNCA) and Erytech Pharma (ERYP)
Erytech Pharma (NASDAQ:ERYP) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, institutional ownership and risk.
Valuation & Earnings
This table compares Erytech Pharma and Genocea Biosciences’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Erytech Pharma||N/A||N/A||-$37.89 million||($3.33)||-2.32|
|Genocea Biosciences||$230,000.00||234.54||-$56.71 million||($1.98)||-0.31|
This is a breakdown of recent ratings for Erytech Pharma and Genocea Biosciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Genocea Biosciences has a consensus target price of $4.00, indicating a potential upside of 542.36%. Given Genocea Biosciences’ higher possible upside, analysts clearly believe Genocea Biosciences is more favorable than Erytech Pharma.
Insider and Institutional Ownership
14.7% of Erytech Pharma shares are owned by institutional investors. Comparatively, 56.9% of Genocea Biosciences shares are owned by institutional investors. 3.0% of Genocea Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Erytech Pharma and Genocea Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Genocea Biosciences beats Erytech Pharma on 7 of the 10 factors compared between the two stocks.
Erytech Pharma Company Profile
ERYTECH Pharma S.A., a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia. It is preparing for the launch of a pivotal Phase III clinical trial of eryaspase in the United States and Europe. ERYTECH Pharma S.A. has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria and with Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. ERYTECH Pharma S.A. was founded in 2004 and is based in Lyon, France.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. Its lead immuno-oncology program is GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in preclinical stage, designed to direct a patient's immune system to attack tumor. The company is also seeking partners to develop cancer vaccines targeting tumor-associated antigens and a vaccine targeting cancers caused by Epstein-Barr virus. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.